Related Experiment Video
Updated: Jul 2, 2026
09:31
Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography
Published on: January 27, 2023
Nesiritide improves hemodynamics in children with dilated cardiomyopathy: a pilot study
Sarina K Behera1, Jennifer C Zuccaro, Glenn T Wetzel
1Department of Pediatrics, University of California, Los Angeles, CA, USA. sarinabehera@yahoo.com
Pediatric Cardiology
|August 16, 2008
Summary
Nesiritide effectively reduced pulmonary capillary wedge pressure, mean pulmonary arterial pressure, and systolic blood pressure in pediatric patients with dilated cardiomyopathy. This study provides key hemodynamic insights for nesiritide use in children.
Area of Science:
- Pediatric Cardiology
- Cardiovascular Pharmacology
- Critical Care Medicine
Background:
- Dilated cardiomyopathy in children presents significant hemodynamic challenges.
- Nesiritide, a natriuretic peptide, is investigated for its potential therapeutic effects in pediatric cardiovascular conditions.
- Hemodynamic assessment is crucial for managing pediatric heart failure.
Purpose of the Study:
- To evaluate the hemodynamic effects of nesiritide in pediatric patients with dilated cardiomyopathy.
- To compare the efficacy of nesiritide versus placebo in altering key hemodynamic parameters.
- To establish the safety and tolerability profile of nesiritide infusion in this population.
Main Methods:
- A prospective, randomized, double-blinded, placebo-controlled pilot study was conducted.
- 20 pediatric patients (<21 years) with dilated cardiomyopathy underwent cardiac catheterization and were randomized to receive nesiritide or placebo.
- Hemodynamic measurements including pulmonary capillary wedge pressure (PCWP), mean pulmonary arterial pressure (MPAP), and systolic blood pressure (SBP) were recorded over 24 hours.
Main Results:
- Nesiritide treatment resulted in significantly greater reductions in PCWP, MPAP, and SBP compared to placebo at 24 hours.
- Mean decrease in PCWP was -5.3 mmHg for nesiritide vs. 1.2 mmHg for placebo (p=0.02).
- Mean decrease in MPAP was -8.0 mmHg for nesiritide vs. 0.4 mmHg for placebo (p=0.006), and SBP decreased by -7.9 mmHg vs. 2.6 mmHg (p=0.04).
Conclusions:
- Nesiritide significantly decreases PCWP, MPAP, and SBP in children with dilated cardiomyopathy.
- These findings support the potential role of nesiritide as a therapeutic agent in pediatric heart failure.
- Further research is warranted to confirm these hemodynamic benefits in a larger pediatric population.
Related Concept Videos
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...